Literature DB >> 20095903

Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions.

Esther Cabrero1, Laura Griffa, Angel Burgos.   

Abstract

Patients infected with HIV treated with highly active antiretroviral therapy (HAART) frequently develop body physical changes (BPC) that have an important psychosocial burden. The purpose of this study was to determine the prevalence of BPC observed by HIV-infected patients and their attending physicians and to assess the impact BPC had on daily life. In this epidemiologic multicenter study, patients with HIV infection and their treating physicians filled out parallel questionnaires about their perceptions of specific BPC and their impact on daily activities. A total of 965 patient-physician questionnaires were collected across 98 health centers. Patient's mean age was 43.7 +/- 8.5 years and 72.6% were men. Adjusted prevalence of perceived BPC by patients and physicians was 55.1% (95% confidence interval [CI]: 52.0-58.1) and 55.2% (95% CI: 52.1-58.2), respectively (p = 1.000). Overall patient-physician agreement concerning perception of BPC was 83% (p < 0.0005). The most common BPC was lipoatrophy, described by 46.8% (95% CI: 43.7-49.8) of patients and 49.4% (95% CI: 46.3-52.5) of physicians (p = 0.033) followed by lipohypertrophy. No gender differences were observed in the global prevalence of BPC (p = 0.649). However, significantly more women reported lipoatrophy of the lower limbs (p = 0.009) and buttocks (p = 0.007), as well as lipohypertrophy (p = 0.007), than men; 58.2% (95% CI: 54.0-62.4) patients noted that BPC negatively affected their daily activities. This study reflects the high prevalence of patient and physician-perceived BPC in the HIV population, and the adverse impact on daily life. Physicians should be aware of the psychosocial consequences of BPC in HIV patients in order to improve patient well-being.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20095903     DOI: 10.1089/apc.2009.0191

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN: 1087-2914            Impact factor:   5.078


  15 in total

1.  Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr.

Authors:  N Agarwal; A Balasubramanyam
Journal:  Adipocyte       Date:  2014-10-30       Impact factor: 4.534

2.  HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity.

Authors:  Nancy Panko; Gerrit Dunford; Rami Lutfi
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

3.  Assessing appearance-related disturbances in HIV-infected men who have sex with men (MSM): psychometrics of the body change and distress questionnaire-short form (ABCD-SF).

Authors:  Aaron J Blashill; Johannes M Wilson; Joshua S Baker; Kenneth H Mayer; Steven A Safren
Journal:  AIDS Behav       Date:  2014-06

4.  A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

Authors:  Jordan E Lake; Grace A McComsey; Todd M Hulgan; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; M Sean Boger; Ralph R Turner; Heather E McCreath; Judith S Currier
Journal:  AIDS Patient Care STDS       Date:  2012-07-23       Impact factor: 5.078

5.  Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes.

Authors:  Priya Bhagwat; Ighovwerha Ofotokun; Grace A McComsey; Todd T Brown; Carlee Moser; Catherine A Sugar; Judith S Currier
Journal:  Antivir Ther       Date:  2017-03-01

6.  Appearance concerns and psychological distress among HIV-infected individuals with injection drug use histories: prospective analyses.

Authors:  Aaron J Blashill; Janna R Gordon; Steven A Safren
Journal:  AIDS Patient Care STDS       Date:  2012-07-13       Impact factor: 5.078

7.  Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders.

Authors:  Charlotte M Verolet; Cécile Delhumeau-Cartier; Marlène Sartori; Simona Toma; Sophie Zawadynski; Minerva Becker; Enos Bernasconi; Laurence Toutous Trellu; Alexandra Calmy
Journal:  AIDS Res Ther       Date:  2015-06-20       Impact factor: 2.250

8.  Depressive symptoms, physical symptoms, and health-related quality of life among older adults with HIV.

Authors:  Blair Olson; Wilson Vincent; Jaimie P Meyer; Trace Kershaw; Kathleen J Sikkema; Timothy G Heckman; Nathan B Hansen
Journal:  Qual Life Res       Date:  2019-08-24       Impact factor: 4.147

9.  Treatment of HIV-associated facial lipoatrophy: impact on infection progression assessed by viral load and CD4 count.

Authors:  Flávia Machado Gonçalves Soares; Izelda Maria Carvalho Costa
Journal:  An Bras Dermatol       Date:  2013 Jul-Aug       Impact factor: 1.896

10.  Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.

Authors:  Todd Hulgan; M Sean Boger; Diana H Liao; Grace A McComsey; Christine A Wanke; Alexandra Mangili; Sharon L Walmsley; Heather McCreath; Ginger L Milne; Stephanie C Sanchez; Judith S Currier; Jordan E Lake
Journal:  Mediators Inflamm       Date:  2014-06-01       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.